A Research Is Being Conducted to Assess the Effectiveness of KM28

A research is being conducted to assess the effectiveness of KM28, a novel medication. The trial will compare KM28 with standard treatment to standard care alone in terms of lowering the risk of recurrent breast cancer. The FDA will approve the new medicine if KM28 with standard treatment reduces the incidence of breast cancer recurrence by at least 40% when compared to conventional therapy alone. On usual treatment, the recurrence rate is reported to be 8%. What is the maximum incidence of recurrent illness acceptable for women treated with KM28 with conventional treatment in order for the FDA to approve KM28?

A) 2) 8%
B) 3) 2%
C) 3) 6%
D) 4) 8%
E) 5) 2%